세계의 매독 검사 시장 : 시장 규모, 점유율 및 동향 분석(기술별, 검사 장소별, 지역별), 부문별 예측(2025-2033년)

Syphilis Testing Market Summary

The global syphilis testing market size was estimated at USD 515.21 million in 2024 and is projected to reach USD 1,375.60 million by 2033, growing at a CAGR of 11.89% from 2025 to 2033. Key market growth drivers for dual HIV/syphilis rapid diagnostics include the rising global burden of congenital syphilis and HIV co-infections, which continue to cause significant adverse pregnancy outcomes.

Growing emphasis on elimination of mother-to-child transmission (EMTCT) programs by the WHO and national health bodies is creating strong demand for cost-effective, point-of-care solutions. Regulatory approvals, such as Health Canada's clearance of MedMira's Multiplo Rapid TP/HIV Test, and partnerships like CHAI-MedAccess-SD Biosensor, are accelerating adoption by ensuring affordability and accessibility. Additionally, the push for decentralized testing in rural and underserved regions supports uptake, while technological improvements in accuracy and speed enhance market confidence.

Syphilis, once considered a disease of the past, has reemerged as a significant public health and market concern in North America and globally. While the widespread use of penicillin in the mid-20th century had nearly eliminated syphilis in high-income countries, recent years have seen a sharp resurgence. In the U.S., reported cases increased by more than 80% between 2018 and 2022, rising from approximately 115,000 to over 207,000-the highest level since the 1950s. Of particular concern is congenital syphilis, which grew by 183% during the same period, reflecting gaps in maternal screening and early intervention. In Canada, rising incidence in the Prairie provinces and northern territories-particularly among Indigenous populations further highlights disparities in access to timely diagnostics and treatment. These epidemiological shifts are creating heightened demand for innovative diagnostic solutions, decentralized testing models, and scalable public health interventions, positioning the infectious disease diagnostics market for accelerated growth.

Global Syphilis Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global syphilis testing market report based on technology, location of testing, cancer type, function, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Diagnostics
• Immunoassay
• Others
• Location of Testing Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Testing
  • Commercial/Private labs
  • Public Health Labs
• Point of Care Testing
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Syphilis Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Technology Segment
    • 1.1.1.2. Location of Testing Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Syphilis Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Technology and Location of Testing Snapshot
• 2.3. Cancer Type and Function Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Syphilis Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
• 3.5. Market Restraint Analysis
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Syphilis Testing Market: Technology Estimates & Trend Analysis

• 4.1. Syphilis Testing Market: Technology Movement Analysis
• 4.2. Molecular Diagnostics
  • 4.2.1. Molecular Diagnostics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.3. Immunoassay
  • 4.3.1. Immunoassay Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.4. Others
  • 4.4.1. Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Syphilis Testing Market: Location of Testing Estimates & Trend Analysis

• 5.1. Syphilis Testing Market: Location of Testing Movement Analysis
• 5.2. Laboratory Testing
  • 5.2.1. Laboratory Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.2. Commercial/Private labs
    • 5.2.2.1. Commercial/Private labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.3. Public Health Labs
    • 5.2.3.1. Public Health Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Point of Care Testing
  • 5.3.1. Point of Care Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Syphilis Testing Market: Regional Business Analysis

• 6.1. Regional Market Snapshot
• 6.2. North America
  • 6.2.1. North America Syphilis Testing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. U.S. Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.2.2.2. Key Country Dynamics
    • 6.2.2.3. Regulatory Framework
    • 6.2.2.4. Reimbursement Scenario
    • 6.2.2.5. Competitive Scenario
  • 6.2.3. Canada
    • 6.2.3.1. Canada Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.2.3.2. Key Country Dynamics
    • 6.2.3.3. Regulatory Framework
    • 6.2.3.4. Reimbursement Scenario
    • 6.2.3.5. Competitive Scenario
  • 6.2.4. Mexico
    • 6.2.4.1. Mexico Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.2.4.2. Key Country Dynamics
    • 6.2.4.3. Regulatory Framework
    • 6.2.4.4. Reimbursement Scenario
    • 6.2.4.5. Competitive Scenario
• 6.3. Europe
  • 6.3.1. Europe Syphilis Testing Market, 2021 - 2033 (USD Million)
  • 6.3.2. UK
    • 6.3.2.1. UK Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.2.2. Key Country Dynamics
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Reimbursement Scenario
    • 6.3.2.5. Competitive Scenario
  • 6.3.3. Germany
    • 6.3.3.1. Germany Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.3.2. Key Country Dynamics
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Reimbursement Scenario
    • 6.3.3.5. Competitive Scenario
  • 6.3.4. Spain
    • 6.3.4.1. Spain Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.4.2. Key Country Dynamics
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Reimbursement Scenario
    • 6.3.4.5. Competitive Scenario
  • 6.3.5. France
    • 6.3.5.1. France Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.5.2. Key Country Dynamics
    • 6.3.5.3. Regulatory Framework
    • 6.3.5.4. Reimbursement Scenario
    • 6.3.5.5. Competitive Scenario
  • 6.3.6. Italy
    • 6.3.6.1. Italy Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.6.2. Key Country Dynamics
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Reimbursement Scenario
    • 6.3.6.5. Competitive Scenario
  • 6.3.7. Denmark
    • 6.3.7.1. Denmark Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.7.2. Key Country Dynamics
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Reimbursement Scenario
    • 6.3.7.5. Competitive Scenario
  • 6.3.8. Sweden
    • 6.3.8.1. Sweden Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.8.2. Key Country Dynamics
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Reimbursement Scenario
    • 6.3.8.5. Competitive Scenario
  • 6.3.9. Norway
    • 6.3.9.1. Norway Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.3.9.2. Key Country Dynamics
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Reimbursement Scenario
    • 6.3.9.5. Competitive Scenario
• 6.4. Asia Pacific
  • 6.4.1. Asia-Pacific Syphilis Testing Market, 2021 - 2033 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Japan Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.4.2.2. Key Country Dynamics
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Scenario
    • 6.4.2.5. Competitive Scenario
  • 6.4.3. China
    • 6.4.3.1. China Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.4.3.2. Key Country Dynamics
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Scenario
    • 6.4.3.5. Competitive Scenario
  • 6.4.4. India
    • 6.4.4.1. India Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.4.4.2. Key Country Dynamics
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Scenario
    • 6.4.4.5. Competitive Scenario
  • 6.4.5. South Korea
    • 6.4.5.1. South Korea Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.4.5.2. Key Country Dynamics
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Reimbursement Scenario
    • 6.4.5.5. Competitive Scenario
  • 6.4.6. Thailand
    • 6.4.6.1. Thailand Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.4.6.2. Key Country Dynamics
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Reimbursement Scenario
    • 6.4.6.5. Competitive Scenario
  • 6.4.7. Australia
    • 6.4.7.1. Australia Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.4.7.2. Key Country Dynamics
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Reimbursement Scenario
    • 6.4.7.5. Competitive Scenario
• 6.5. Latin America
  • 6.5.1. Latin America Syphilis Testing Market, 2021 - 2033 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Brazil Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.5.2.2. Key Country Dynamics
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Scenario
    • 6.5.2.5. Competitive Scenario
  • 6.5.3. Argentina
    • 6.5.3.1. Argentina Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.5.3.2. Key Country Dynamics
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Scenario
    • 6.5.3.5. Competitive Scenario
• 6.6. MEA
  • 6.6.1. MEA Syphilis Testing Market, 2021 - 2033 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. South Africa Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.6.2.2. Key Country Dynamics
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Scenario
    • 6.6.2.5. Competitive Scenario
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Saudi Arabia Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.6.3.2. Key Country Dynamics
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Scenario
    • 6.6.3.5. Competitive Scenario
  • 6.6.4. UAE
    • 6.6.4.1. UAE Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.6.4.2. Key Country Dynamics
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Scenario
    • 6.6.4.5. Competitive Scenario
  • 6.6.5. Kuwait
    • 6.6.5.1. Kuwait Syphilis Testing Market, 2021 - 2033 (USD Million)
    • 6.6.5.2. Key Country Dynamics
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Scenario
    • 6.6.5.5. Competitive Scenario

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
  • 7.2.1. New Product Launch
  • 7.2.2. Partnerships
  • 7.2.3. Acquisition
  • 7.2.4. Collaboration
  • 7.2.5. Funding
• 7.3. Key Company Market Share Analysis, 2024
• 7.4. Company Heat Map Analysis
• 7.5. Company Profiles
  • 7.5.1. Abbott Laboratories
    • 7.5.1.1. Company Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Bio-Rad Laboratories, Inc.
    • 7.5.2.1. Company Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. F. Hoffmann-La Roche Ltd
    • 7.5.3.1. Company Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Siemens Healthineers AG
    • 7.5.4.1. Company Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Danaher Corporation (Beckman Coulter)
    • 7.5.5.1. Company Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
  • 7.5.6. bioMerieux SA
    • 7.5.6.1. Company Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Thermo Fisher Scientific, Inc.
    • 7.5.7.1. Company Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. OraSure Technologies, Inc.
    • 7.5.8.1. Company Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Chembio Diagnostics, Inc.
    • 7.5.9.1. Company Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. SD Biosensor, Inc.
    • 7.5.10.1. Company Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives